



*cancers*



an Open Access Journal by MDPI

## Treg Cell Immunotherapy in Cancer

Guest Editor:

**Dr. Maria Velegraki**

Pelotonia Institute for Immuno-  
Oncology, The Ohio State  
University Comprehensive  
Cancer Center, Columbus, OH  
43210, USA

Deadline for manuscript  
submissions:

**28 February 2025**

### Message from the Guest Editor

Dear Colleagues,

Depleting Treg cells from the tumor microenvironment has the potential to immensely improve antitumor immune responses, but Treg targeting approaches are being challenged by 2 main issues: (i) Treg cells share many markers with conventional T cells and therefore cannot be utilized as targets to specifically eradicate Treg cells without interfering with effector functions, (ii) universal Treg cell depletion can be complicated with severe autoimmunity.

This issue of *Cancers* is dedicated to this topic, aiming to contribute to better understanding of the aspects of Treg biology which shape antitumor immune responses and the potential of developing successful Treg targeting therapeutic interventions to improve cancer immunotherapy. We aim to cover all associated areas, including but not limited to the mechanisms of Treg cell migration, adaptation and survival in the tumor microenvironment, mechanisms of Treg mediated suppression of antitumor immune responses, and mainly novel therapeutic approaches to target Treg cells specifically in the tumor without causing autoimmune phenomena or interfering with effector functions.



[mdpi.com/si/167403](https://mdpi.com/si/167403)

# Special Issue



# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI